

CASE STUDY FROM FAMILY PLANNING

Martha Brady, Population Council


PDP Access Group Meeting

May 21-22, 2014

2012 London Summit on Family Planning

- Global leaders pledged to provide an additional 120 million women in developing countries contraceptive access by 2020.
- UN Commission on Life-Saving Commodities tasked with helping to shape global markets by offering commodities at optimal price and volume.

Global Contraceptives Market



- New technologies hold potential for expanding individual choice and increasing contraceptive prevalence
- Opportunity for public and private sector actors

International Donors Get Bayer to Cut Price of Implantable Birth Control for the Poor

- Bayer AG, will halve the \$18 price of its implantable contraceptive for **27 million women** in poor countries under a deal worked out with:
 - BMGF
 - CHAI
 - Governments of Norway, United Kingdom, United States and Sweden
 - Children’s Investment Fund Foundation
 - United Nations Population Fund

Some Strategies we Have /Will Try

Reducing COGS by:


- Process optimization (mechanization, scaling)
- API cost reduction (move from single supplier)
- Site of manufacturing (must ensure GMP)

Reduce price by:

- Pooled procurement (by region, by agency)
- Negotiate pricing terms (e.g. volume guarantee)
- Product bundling - evidence of effectiveness?

Must have: Ability to commit funds or bring in donors to support pricing structures

Global Reproductive Health Landscape



Preparing for Access, Uptake Planning. Too early? Too late?



Frameworks for “Introduction,” “Uptake,” “Access,” “Adoption”

Numerous Frameworks, Common Elements:

- Assessment of service systems’ capacity
- Building Support: policy, financial, provider
- Developing cadre of local champions
- Regulatory Approval and Licensure
- Development of distribution plans
- Creation of Provider Training
- Development of communication strategy
- Monitoring and Evaluation
- Operations Research

Proof of Deliverability

- **Why this product ?** Clear understanding (on part of policymakers, providers) of product benefit (evidence based, data driven hopefully)
- **Capacity** of health *systems* and *providers* to deliver product with quality and safety
 - Demonstrated feasibility of delivery to end user
 - Targeted health systems strengthening
- **Affordability** and **acceptability** (to consumer, program, funder)
- **Access** and actual **use** by “key” population groups can be achieved
- **Longer-term outcomes:** how X fits into overall mix of interventions (e.g. contraceptive method mix)



Suite of Tools

A TOOLKIT FOR STRATEGIC DECISIONMAKING AND PLANNING FOR MICROBICIDES

MODULE 3
PROGRAM PLANNING GUIDE

This Guide is designed to stimulate discussion among selected service providers, policy makers, and program managers. It provides a sample work process that facilitates a facility-based, client-centered, and data-driven approach to program planning. It also provides a framework for considering clients' rights.

MODULE 2
DISCUSSION GUIDE FOR KEY OPINION LEADERS AND DECISION-MAKERS

This tool is designed to facilitate a discussion about the HIV epidemic, health information systems, and health information systems capacity and address the needs of key opinion leaders and decision-makers. It also provides a framework for considering clients' rights.

MODULE 1
LANDSCAPE ANALYSIS

This tool is to be used to facilitate a desk review, which consists primarily of a desk review, interviews with key informants, and a review of the literature. It is designed to provide a clear picture of the current environment and shape of the HIV epidemic in the target area. It also provides a framework for considering clients' rights.

APPENDIX 1
SELECTED PROGRAM/POLICY TOOLS REVIEWED IN SUPPORT OF STRATEGY ELEMENT #4 OF USAID'S PROPOSAL FOR A SHARED VISION AND STRATEGIC PLAN FOR MICROBICIDE INTRODUCTION

ILLUSTRATIVE AGENDA: PROGRAM PLANNING FOR TENOFOVIR GEL INTRODUCTION

This document provides an illustrative agenda for a consultation and facilitated discussion on introducing tenofovir gel. It is designed to be used in conjunction with the discussion guide for key opinion leaders and decision-makers.

APPENDIX 2
INTRODUCING TENOFOVIR GEL: A CHECKLIST FOR SERVICE DELIVERY

This checklist is designed to ensure that the introduction of tenofovir gel is done in a safe and effective manner. It is designed to be used by program managers and health providers to determine if a client and her healthcare provider are ready for the introduction of tenofovir gel.

A TOOLKIT FOR STRATEGIC DECISIONMAKING AND PLANNING FOR MICROBICIDES

TOOLKIT

EPIDEMIOLOGICAL CONTEXT

- Describe the HIV epidemic
 - National prevalence
 - Regional prevalence
 - Trends in prevalence
 - Populations with high prevalence
 - AIDS-related mortality
 - Coverage of antiretroviral therapy
 - Important risk factors
 - Intravaginal sex
 - Contraception
 - Tuberculosis
 - Age at first sex
 - Most at risk
- Describe prevalent infections (STIs)
- Describe current contraceptive methods
- Describe overall reproductive health
 - Total fertility rate
 - Maternal mortality ratio
 - Region
- Describe reproductive health services

USAID **Population Council**

Research for Introducing Interventions

Research domain/type	Evidence generated	Users of evidence	Research methods
Operational	Solutions to operational problems of specific health programs or other service delivery components of the health system	Service providers Program managers	Readiness assessments Systematic monitoring Small-scale experimental studies Qualitative studies Modelling
Implementation	Strategies to improve access to and use of available or new interventions by the populations in need	Program managers Policymakers	Prospective experimental designs Multi-centre, multi-disciplinary studies Economic analyses
Health system	Understanding of the health system adaptations needed to integrate and routinely offer new interventions	Policymakers	Organizational research Policy analyses Economic analyses

Ideas. Evidence. Impact.



The Population Council conducts research and delivers solutions that improve lives around the world. Big ideas supported by evidence: It's our model for global change.